Ivosidenib in acute myeloid leukemia

References

• Im AP, Sehgal AR, Carroll MP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia. 2014;28(9):1774–1783. doi: 10.1038/leu.2014.124
   PubMed Web of Science ®Google Scholar
• Schnittger S, Haferlach C, Ulke M, et al. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood. 2010;116(25):5486–5496. doi: 10.1182/blood-2010-02-267955
   PubMed Web of Science ®Google Scholar
• Patel KP, Ravandi F, Ma D, et al. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol. 2011;135(1):35–45. doi: 10.1309/AJCPD7NR2RMNQDVF
   PubMed Web of Science ®Google Scholar
• Dunlap JB, Leonard J, Rosenberg M, et al. The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML. Am J Hematol. 2019;94(8):913–920. doi: 10.1002/ajh.25517
   PubMed Web of Science ®Google Scholar
• Xu Q, Li Y, Lv N, et al. Correlation between isocitrate dehydrogenase gene aberrations and prognosis of patients with acute myeloid leukemia: a systematic review and meta-analysis. Clin Cancer Res. 2017;23(15):4511–4522. doi: 10.1158/1078-0432.CCR-16-2628
   PubMed Web of Science ®Google Scholar
• Daver N, Wei AH, Pollyea DA, et al. New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J. 2020;10(10):107. doi: 10.1038/s41408-020-00376-1
   PubMed Web of Science ®Google Scholar
• Molenaar RJ, Maciejewski JP, Wilmink JW, et al. Wild-type and mutated IDH1/2 enzymes and therapy responses. Oncogene. 2018;37(15):1949–1960. doi: 10.1038/s41388-017-0077-z
   PubMed Web of Science ®Google Scholar
• Grassian AR, Parker SJ, Davidson SM, et al. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. Cancer Res. 2014;74(12):3317–3331. doi: 10.1158/0008-5472.CAN-14-0772-T
   PubMed Web of Science ®Google Scholar
• Scourzic L, Mouly E, Bernard OA. TET proteins and the control of cytosine demethylation in cancer. Genome Med. 2015;7(1):9. doi: 10.1186/s13073015-0134-6
   PubMedGoogle Scholar
• Ye D, Guan K-L, Xiong Y. Metabolism, activity and targeting of D- and L-2Hydroxyglutarates. Trends Cancer. 2018;4(2):151–165. doi: 10.1016/j.trecan.2017.12.005
   PubMed Web of Science ®Google Scholar
• Sasaki M, Knobbe CB, Munger JC, et al. IDH1 (R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature. 2012;488(7413):656–659. doi: 10.1038/nature11323
   PubMed Web of Science ®Google Scholar
• Chen C, Liu Y, Lu C, et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev. 2013;27(18):1974–1985. doi: 10.1101/gad.226613.113
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553–567. doi: 10.1016/j.ccr.2010.11.015
   PubMed Web of Science ®Google Scholar
• Parker SJ, Metallo CM. Metabolic consequences of oncogenic IDH mutations. Pharmacol Ther. 2015;152:54–62. doi: 10.1016/j.pharmthera.2015.05.003
   PubMed Web of Science ®Google Scholar
• Rashkovan M, Ferrando A. Metabolic dependencies and vulnerabilities in leukemia. Genes Dev. 2019;33(21–22):1460–1474. doi: 10.1101/gad.326470.119
   PubMed Web of Science ®Google Scholar
• Popovici-Muller J, Lemieux RM, Artin E, et al. Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett. 2018;9(4):300–305. doi: 10.1021/acsmedchemlett.7b00421
   PubMed Web of Science ®Google Scholar
• Dai D, Yang H, Nabhan S, et al. Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects. Eur J Clin Pharmacol. 2019 Aug;75(8):1099–1108. Epub 2019 Apr 23. PMID: 31011758. doi: 10.1007/s00228-019-02673-6
   PubMed Web of Science ®Google Scholar
• Megías-Vericat JE, Solana-Altabella A, Ballesta-López O, et al. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. Ann Hematol. 2020;99(9):1989–2007. doi: 10.1007/s00277-020-04186-0
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018 Jun 21;378(25):2386–2398. Epub 2018 Jun 2. PMID: 29860938. doi: 10.1056/NEJMoa1716984
   PubMed Web of Science ®Google Scholar
• Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020 Feb 13;135(7):463–471. PMID: 31841594; PMCID PMC7019193. doi: 10.1182/blood.2019002140
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein AS, Al SE. Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia. J Clin Oncol. 2021 Jan;39(1):57–65. Epub 2020 Oct 29. Erratum in: J Clin Oncol. 2021 Feb 1;39(4):341. PMID: 33119479; PMCID: PMC7771719. doi: 10.1200/JCO.20.01632
   PubMed Web of Science ®Google Scholar
• Montesinos P, Recher C, Al VS. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022 Apr 21;386(16):1519–1531. PMID: 35443108. doi: 10.1056/NEJMoa2117344
   PubMed Web of Science ®Google Scholar
• Lachowiez CA, Garcia JC, Borthakur G, et al. A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated hematologic malignancies. J Clin Oncol. 2022;40:16_suppl, 7018–7018. doi: 10.1200/JCO.2022.40.16_suppl.7018
   Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Fathi AT, et al. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021 Apr 1;137(13):1792–1803. PMID: 33024987; PMCID: PMC8020270. doi: 10.1182/blood.2020007233
   PubMed Web of Science ®Google Scholar
• A China bridging study of ivosidenib in r/r AML subjects with an IDH1 mutation. https://classic.clinicaltrials.gov/ct2/show/NCT04176393
   Google Scholar
• A study of Gilteritinib in combination with ivosidenib or enasidenib in people with acute myeloid leukemia (AML) https://classic.clinicaltrials.gov/ct2/show/NCT05756777
   Google Scholar
• Decitabine/Cedazuridine and venetoclax in combination with ivosidenib or enasidenib for the treatment of relapsed or refractory acute Myeloid Leukemia https://classic.clinicaltrials.gov/ct2/show/NCT04774393
   Google Scholar
• IDH Targeted/Non- Targeted vs non-targeted/IDH-targeted approaches in the treatment of newly diagnosed IDH mutated AML patients not candidates for intensive induction therapy (I- DATA study). https://clinicaltrials.gov/study/NCT05401097?cond=Acute%20Myeloid%20Leukemia&term=ivosidenib&rank=5
   Google Scholar
• Ivosidenib and venetoclax with or without azacitidine in treating patients with IDH1 mutated hematologic malignancies https://classic.clinicaltrials.gov/ct2/show/NCT03471260
   Google Scholar
• CPX-351 and ivosidenib for the treatment of IDH1 mutated acute myeloid leukemia or high-risk myelodysplastic syndrome. https://classic.clinicaltrials.gov/ct2/show/NCT04493164
   Google Scholar
• A study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy, followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myedysplastic syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML) https://classic.clinicaltrials.gov/ct2/show/NCT03839771
   Google Scholar
• Decitabine alone or in combination with venetoclax, Gilteritinib, enasidenib, or ivosidenib as maintenance therapy for the treatment of acute myeloid leukemia in Remission https://classic.clinicaltrials.gov/ct2/show/NCT05010772
   Google Scholar
• Bruzzese A, Martino EA, Labanca C, et al. Glasdegib for the treatment of acute myeloid leukemia. Expert Opin Pharmacother. 2023 Jul 3:1–7. doi: 10.1080/14656566.2023.2232301. Epub ahead of print. Erratum in: Expert Opin Pharmacother. 2023 Jul 17;1. PMID: 37392098.
   Web of Science ®Google Scholar
• Bruzzese A, Martino EA, Al MF. Venetoclax in acute myeloid leukemia. Expert Opin Investig Drugs. 2023 Apr;32(4):271–276. Epub 2023 Mar 23. PMID: 36933006. doi: 10.1080/13543784.2023.2193679
   PubMed Web of Science ®Google Scholar
• Bayraktar EA, Küçükyurt S, Eşkazan AE. Recent advances in the therapeutic armamentarium of acute myeloid leukemia: a focus on the 63rd American Society of Hematology Annual Meeting Abstracts. Curr Pharm Des. 2022 Sep;12:2687–2689. Epub ahead of print. PMID: 36093823. doi: 10.2174/1381612828666220912092158
   Google Scholar
• Kucukyurt S, Eskazan AE. New drugs approved for acute myeloid leukaemia in 2018. Br J Clin Pharmacol. 2019 Dec;85(12):2689–2693. Epub 2019 Dec 13. PMID: 31469910; PMCID: PMC6955409. doi: 10.1111/bcp.14105
   PubMed Web of Science ®Google Scholar
• Cerchione C, Romano A, Daver N, et al. IDH1/IDH2 inhibition in acute myeloid leukemia. Front Oncol. 2021 Mar 29;11:639387. PMID: 33898313; PMCID: PMC8063727. doi: 10.3389/fonc.2021.639387
   PubMedGoogle Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in Previously untreated acute myeloid leukemia. N Engl J Med. 2020 Aug 13;383(7):617–629. PMID: 32786187. doi: 10.1056/NEJMoa2012971
   PubMed Web of Science ®Google Scholar
• Stuani L, Sabatier M, Saland E, et al. Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. J Exp Med. 2021 May 3;218(5):e20200924. PMID: 33760042; PMCID: PMC7995203. doi: 10.1084/jem.20200924
   PubMed Web of Science ®Google Scholar
• Wang F, Morita K, DiNardo CD, et al. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun. 2021 May 10;12(1):2607. PMID: 33972549; PMCID: PMC8110775. doi: 10.1038/s41467-021-22874-x
   PubMed Web of Science ®Google Scholar